Multifactorial resistance in patients with acute myeloid leukemia (AML): Coexpression of P-glycoprotein, the multidrug-resistance related protein (MRP) as well as heat shock proteins

1995 ◽  
Vol 121 (S1) ◽  
pp. A46-A46
Author(s):  
S. Kasimir-Bauer ◽  
W. Stellberg ◽  
C. Schardt ◽  
M. E. Scheulen ◽  
S. Seeber
2005 ◽  
Vol 29 (9) ◽  
pp. 1049-1058 ◽  
Author(s):  
Xavier Thomas ◽  
Lydia Campos ◽  
Christiane Mounier ◽  
Jérome Cornillon ◽  
Pascale Flandrin ◽  
...  

Blood ◽  
1999 ◽  
Vol 94 (7) ◽  
pp. 2414-2423 ◽  
Author(s):  
Mariëlle E.P. Smeets ◽  
Reinier A.P. Raymakers ◽  
Gerty Vierwinden ◽  
Arie H.M. Pennings ◽  
Hans Wessels ◽  
...  

Expression of the multidrug resistance (MDR) mechanisms P-glycoprotein (Pgp) and MDR-related protein (MRP) decrease cellular retention and consequently cytotoxicity of anthracyclines. MDR is expressed on normal human hematopoietic progenitors and leukemic blasts. Normal CD34+ progenitors showed rhodamine efflux in 20% to 30% of the cells, which could be blocked by verapamil. These cells appeared noncycling, in contrast to the proliferating rhodamine bright (RhoB) cells. We postulated that MDR expression can be downregulated by proliferation induction. Triggering rhodamine dull (RhoD) CD34+ cells to proliferate indeed resulted in a higher rhodamine retention and significantly decreased efflux modulation by verapamil (P = .04). Also in acute myeloid leukemia (AML), the proliferation rate (percentage S/G2+M and Iododeoxyuridine labelings index) was significantly less in the RhoD blasts (P ≤ .008) and proliferation induction of RhoD blasts resulted in increased rhodamine retention. Anthracycline cytotoxicity was less for RhoD than RhoB cells in both normal progenitors and leukemic blasts. Proliferation induction of the RhoD cells resulted in increased anthracycline sensitivity. We conclude that noncycling progenitors, both normal and leukemic, have a relatively high MDR expression. Triggering these cells into proliferation downregulates MDR expression. These findings can be exploited to overcome MDR in the treatment of AML patients.


2014 ◽  
Vol 13 (1) ◽  
pp. 116 ◽  
Author(s):  
Ingvild Haaland ◽  
Jill A Opsahl ◽  
Frode S Berven ◽  
Håkon Reikvam ◽  
Hanne K Fredly ◽  
...  

2020 ◽  
Vol 42 (5) ◽  
pp. 594-603
Author(s):  
Lenilton Silva da Silveira Júnior ◽  
Victor de Lima Soares ◽  
Alessandra Suelen Jardim da Silva ◽  
Erica Aires Gil ◽  
Maria das Graças Pereira de Araújo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document